ProPublica

Journalism in the Public Interest

Cancel

UCB

UCB is a drug company based in Brussels, Belgium. Its U.S. subsidiary agreed to plead guilty in June 2011 and pay more than $34 million related to allegations that it promoted its epilepsy drug Keppra for unapproved uses.

UCB began reporting payments on food, gifts, consulting payments, travel, speaking fees and other similar exchanges as of January 2012. UCB combines all categories into a single amount.

See all UCB payments, or visit UCB's transparency page.

Notable drugs

Payment Reports

2012 Jan. to Dec.

Avg. Quarterly Total
Combination $7,520,911 $30,083,643
$7,520,911 $30,083,643

Total Payments by State

State Total
New York $3,931,291
California $3,185,454
Texas $2,649,189
North Carolina $2,293,985
Florida $2,183,184
Pennsylvania $1,140,463
Georgia $958,998
Michigan $950,691
Arizona $912,022
Ohio $803,804
Illinois $751,878
Arkansas $614,389
New Jersey $606,085
Maryland $595,683
Colorado $582,275
Tennessee $577,049
Kentucky $551,948
Alabama $504,397
Missouri $499,272
Washington $454,686
Connecticut $426,941
Louisiana $398,817
Nebraska $387,770
Minnesota $374,373
Massachusetts $374,067
Virginia $373,753
Wisconsin $315,420
Oklahoma $299,814
Indiana $277,652
Idaho $238,464
Nevada $233,274
South Carolina $233,203
West Virginia $225,857
Mississippi $137,661
Kansas $128,339
Rhode Island $122,883
Iowa $119,368
Utah $96,403
New Mexico $91,611
District of Columbia $89,388
Oregon $89,263
New Hampshire $72,600
Puerto Rico $65,915
Vermont $43,569
Hawaii $26,649
South Dakota $24,777
Maine $23,679
Montana $22,081
Delaware $17,754
Alaska $2,250
North Dakota $1,968
Wyoming $1,325
[Unknown State] $14